Drugs / Perphenazine
Perphenazine
also known as
Trilafon · Chlorpiprazine · Decentan · Fentazin · NSC-150866 · PER · Perfenazina · Perphenazine component of etrafon-a · +2 more
Small molecule targets DRD2, NOX4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TRILAFON | — | 1957-02-27 | fda.gov ↗ |
Trials 13 · a red edge is where a trial was stopped
1956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04776499 | Mar 2021 → Feb 2022 | — | Maastricht University | Completed | No outcome recorded |
| Phase 1 | NCT00480246 | May 2007 → ? | — | BioLineRx, Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05762146 | Sep 2022 → Feb 2024 | ischemic stroke | Maastricht University | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03510325 | Feb 2019 → Sep 2023 | schizophrenia | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT00009204 | Sep 1995 → Apr 2000 | Alzheimer disease, vascular dementia | Bruce Pollock | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02307396 | Feb 2015 → Jun 2016 | schizoaffective disorder, schizophrenia | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT00806234 | Jan 2009 → Mar 2014 | psychotic disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT00802100 | Dec 2008 → Sep 2009 | schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00014001 | Dec 2000 → Dec 2004 | schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02192723 | Jun 2012 → Jun 2014 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT03019887 | Apr 2011 → Jan 2017 | schizophrenia | Juntendo University | Completed | No outcome recorded |
| — | NCT00493233 | Nov 2006 → Dec 2008 | schizophrenia | Centre for Addiction and Mental Health | Completed | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00737256 Comparator | Aug 2008 → May 2013 | cocaine dependence, schizophrenia | Paul Saenger | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04606264 Comparator | May 2023 → Mar 2025 | — | Jennifer Holder-Murray | Completed | No outcome recorded |
| Phase 3 | NCT02431702 Comparator | Jul 2015 → Nov 2019 | schizophrenia | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02199743 Comparator | Feb 2013 → Jun 2016 | schizoaffective disorder, schizophrenia | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01193166 Comparator | Aug 2010 → Sep 2012 | schizophrenia | Ortho-McNeil Janssen Scientific Affairs, LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT01157351 Comparator | May 2010 → Dec 2013 | schizophrenia | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | perphenazine | “Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks” NCT02192723 ↗ |
| Known as | Chlorpiprazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL567 ↗ |
| Known as | Decentan | ChEMBL registry synonym — accepted as the source's own label CHEMBL567 ↗ |
| Known as | Fentazin | ChEMBL registry synonym — accepted as the source's own label CHEMBL567 ↗ |
| Known as | NSC-150866 | ChEMBL registry synonym — accepted as the source's own label CHEMBL567 ↗ |
| Known as | PER | “1. 320 begin double-blind treatment with perphenazine (PER)” NCT00014001 ↗ |
| Known as | Perfenazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL567 ↗ |
| Known as | Perphenazine component of etrafon-a | ChEMBL registry synonym — accepted as the source's own label CHEMBL567 ↗ |
| Known as | Perphenazine maleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL567 ↗ |
| Known as | Trilafon | “Perphenazine (Trilafon®, hereafter called Perphenazine)” NCT00480246 ↗1“Perphenazine [Trilafon]” NCT00009204 ↗ |
| Known as | Trilafon-la | ChEMBL registry synonym — accepted as the source's own label CHEMBL567 ↗ |
| Action | Inhibit | “perphenazine, a typical antipsychotic, and propylthiouracil, a thyroid peroxidase inhibitor used for the treatment of hyperthyroidism, have previously been identified as...” NCT04776499 ↗1“Dopamine D2 receptor antagonist” CHEMBL567 ↗ |
| Modality | Small molecule | — CHEMBL567 ↗ |
| Route | Oral | “single oral doses of BL-1020 or Perphenazine” NCT00480246 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL567 ↗ |
| Target | NOX4 | “perphenazine, a typical antipsychotic, and propylthiouracil, a thyroid peroxidase inhibitor used for the treatment of hyperthyroidism, have previously been identified as...” NCT04776499 ↗ |